Scientific Publications and Presentations

Science That Moves Neuroscience Forward

Our scientific publications reflect our commitment to advancing neuroscience through rigorous research, transparent data sharing, and ongoing collaboration with the scientific community.

Search by Keyword

Filter by Focus Area

Filter by Year

Filter by Meeting

2026 | AAN Annual Meeting

Evaluating the Therapeutic Potential of Emerging Precision Sodium Channel Modulators in Pain

2026 | AAN Annual Meeting

PAC-PAIN: Application of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Pain Models

2026 | AAN Annual Meeting

PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies

2026 | AAN Annual Meeting

Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy

2026 | AAN Annual Meeting

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus

2026 | AAN Annual Meeting

POWER1 – A Double-blind, Randomized, Multicenter Phase 2/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures

2026 | AAN Annual Meeting

Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-resistant Epilepsy: Results from the RADIANT Study

2026 | AAN Annual Meeting

High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from the EMPOWER Observational Study and a US Real-world Claims Analysis

2026 | AAN Annual Meeting

Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants

2026 | AAN Annual Meeting

EMERALD: A Phase 3, Randomized, Multi-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies

Explore More

Pipeline

Explore our pipeline of investigational therapies targeting biologically defined mechanisms across essential tremor, DEEs, and epilepsy.

Our Science

Learn how insights from genetics, neuronal excitability, and disease biology inform our approach to developing potential therapies for neurologic disorders.

Scientific Publications and Presentations

Science That Moves Neuroscience Forward

Evaluating the Therapeutic Potential of Emerging Precision Sodium Channel Modulators in Pain

PAC-PAIN: Application of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Pain Models

PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies

Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus

POWER1 – A Double-blind, Randomized, Multicenter Phase 2/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures

Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-resistant Epilepsy: Results from the RADIANT Study

High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from the EMPOWER Observational Study and a US Real-world Claims Analysis

Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants

EMERALD: A Phase 3, Randomized, Multi-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies

Explore More

Pipeline

Our Science

99 High Street, 30th FloorBoston, MA 02110

Built for Possibility

99 High Street, 30th Floor
Boston, MA 02110